Skip to main content
. Author manuscript; available in PMC: 2011 Dec 6.
Published in final edited form as: Mol Pharm. 2010 Sep 29;7(6):2120–2131. doi: 10.1021/mp100226q

Figure 3.

Figure 3

Figure 3

FCFP_6 features associated with OCTN2 non-inhibitors. Each of the 20 panels shows the naming convention for one fragment, the numbers of inhibitors containing the fragment, and the Bayesian score for the fragment. In all cases, a compound containing any of these 20 fragments was not an OCTN2 inhibitor.